The Role of Peroxisome Proliferator-Activated Receptor and Effects of Its Agonist, Pioglitazone, on a Rat Model of Optic Nerve Crush: PPARγ in Retinal Neuroprotection

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Zhu, Juming ^a   Zhang, Junfang ^a   Ji, Min ^a   Gu, Hongwei ^a   Xu, Yue ^a   Chen, Chen ^a   Hu, Nan ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MUELLER CELL; NEUROPROTECTION; NONHUMAN; OPTIC NERVE CRUSH; OPTIC NERVE INJURY; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETINA GANGLION CELL;

ANALYSIS OF VARIANCE; ANILIDES; ANIMALS; BLOTTING, WESTERN; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; NEUROPROTECTIVE AGENTS; OPTIC NERVE INJURIES; PPAR GAMMA; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL GANGLION CELLS; THIAZOLIDINEDIONES;

EID: 84880448216     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068935     Document Type: Article

References (39)

1. Schmidt KG, Bergert H, Funk RH, (2008) Neurodegenerative diseases of the retina and potential for protection and recovery. Curr Neuropharmacol 6: 164-178.
2. Kisiswa L, Dervan AG, Albon J, Morgan JE, Wride MA, (2010) Retinal ganglion cell death postponed: giving apoptosis a break? Ophthalmic Res 43: 61-78.
3. Quigley HA, McKinnon SJ, Zack DJ, Pease ME, Kerrigan-Baumrind LA, et al. (2000) Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci 41: 3460-3466.
4. Sucher NJ, Lipton SA, Dreyer EB, (1997) Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res 37: 3483-3493.
5. Tezel G, (2006) Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res 25: 490-513.
6. Neufeld AH, Liu B, (2003) Glaucomatous optic neuropathy: when glia misbehave. Neuroscientist 9: 485-495.
7. Leung CK, Lindsey JD, Crowston JG, Lijia C, Chiang S, et al. (2008) Longitudinal profile of retinal ganglion cell damage after optic nerve crush with blue-light confocal scanning laser ophthalmoscopy. Invest Ophthalmol Vis Sci 49: 4898-4902.
8. Chidlow G, Wood JP, Casson RJ, (2007) Pharmacological neuroprotection for glaucoma. Drugs 67: 725-759.
9. Fu QL, Li X, Yip HK, Shao Z, Wu W, et al. (2009) Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience 162: 375-382.
10. Vidal-Sanz M, Lafuente M, Sobrado-Calvo P, Selles-Navarro I, Rodriguez E, et al. (2000) Death and neuroprotection of retinal ganglion cells after different types of injury. Neurotox Res 2: 215-227.
11. Kusari J, Zhou S, Padillo E, Clarke KG, Gil DW, (2007) Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 48: 5152-5159.
12. Wilhelm B, Ludtke H, Wilhelm H, (2006) Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol 244: 551-558.
13. Escher P, Wahli W, (2000) Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 448: 121-138.
14. Rosen ED, Spiegelman BM, (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731-37734.
15. Lehrke M, Lazar MA, (2005) The many faces of PPARgamma. Cell 123: 993-999.
16. Escribano L, Simon AM, Perez-Mediavilla A, Salazar-Colocho P, Del Rio J, et al. (2009) Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 379: 406-410.
17. Carta AR, Frau L, Pisanu A, Wardas J, Spiga S, et al. (2011) Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience 194: 250-261.
18. Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF, (2005) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 191: 331-336.
19. Esposito E, Cuzzocrea S, (2011) Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury. Expert Opin Ther Targets 15: 943-959.
20. Qi L, Jacob A, Wang P, Wu R, (2010) Peroxisome proliferator activated receptor-gamma and traumatic brain injury. Int J Clin Exp Med 3: 283-292.
21. Lee CH, Park OK, Yoo KY, Byun K, Lee B, et al. (2011) The role of peroxisome proliferator-activated receptor gamma, and effects of its agonist, rosiglitazone, on transient cerebral ischemic damage. J Neurol Sci 300: 120-129.
22. Vigneswara V, Berry M, Logan A, Ahmed Z, (2012) Pharmacological inhibition of caspase-2 protects axotomised retinal ganglion cells from apoptosis in adult rats. PLoS One 7: e53473.
23. Mabuchi F, Aihara M, Mackey MR, Lindsey JD, Weinreb RN, (2004) Regional optic nerve damage in experimental mouse glaucoma. Invest Ophthalmol Vis Sci 45: 4352-4358.
24. Mackenzie P, Cioffi G, (2008) How does lowering of intraocular pressure protect the optic nerve? Surv Ophthalmol 53 Suppl1: S39-43.
25. Schwartz M, (2004) Optic nerve crush: protection and regeneration. Brain Res Bull 62: 467-471.
26. Goldblum D, Mittag T, (2002) Prospects for relevant glaucoma models with retinal ganglion cell damage in the rodent eye. Vision Res 42: 471-478.
27. Michalik L, Desvergne B, Dreyer C, Gavillet M, Laurini RN, et al. (2002) PPAR expression and function during vertebrate development. Int J Dev Biol 46: 105-114.
28. Pershadsingh HA, Moore DM, (2008) PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies. PPAR Res 2008: 164273.
29. Herzlich AA, Ding X, Shen D, Ross RJ, Tuo J, et al. (2009) Peroxisome Proliferator-Activated Receptor Expression in Murine Models and Humans with Age-related Macular Degeneration. Open Biol J 2: 141-148.
30. Sarayba MA, Li L, Tungsiripat T, Liu NH, Sweet PM, et al. (2005) Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand. Exp Eye Res 80: 435-442.
31. Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J, (2006) Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 20: 1162-1175.
32. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R, (2008) PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 1244: 164-172.
33. Bernardo A, Levi G, Minghetti L, (2000) Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci 12: 2215-2223.
34. Aoun P, Simpkins JW, Agarwal N, (2003) Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest Ophthalmol Vis Sci 44: 2999-3004.
35. Victor NA, Wanderi EW, Gamboa J, Zhao X, Aronowski J, et al. (2006) Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur J Neurosci 24: 1653-1663.
36. Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, et al. (2006) Muller cells in the healthy and diseased retina. Prog Retin Eye Res 25: 397-424.
37. Nakazawa T, Matsubara A, Noda K, Hisatomi T, She H, et al. (2006) Characterization of cytokine responses to retinal detachment in rats. Mol Vis 12: 867-878.
38. Tura A, Schuettauf F, Monnier PP, Bartz-Schmidt KU, Henke-Fahle S, (2009) Efficacy of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina. Invest Ophthalmol Vis Sci 50: 452-461.
39. Bringmann A, Wiedemann P, (2012) Muller glial cells in retinal disease. Ophthalmologica 227: 1-19.